AMCP 2024: Behind the research with YuQian Liu - Prime Therapeutics
AMCP 2024: Behind the research with YuQian Liu
Ahead of her session with Andy Killpack, Liu — senior director of specialty clinical solutions at Prime/MRx — shares current care management strategies for cell and gene therapy and the future of this exciting frontier
As more high-priced cell and gene therapies come onto the market, the health care industry is faced with a fundamental challenge: to make sure that patients can access these life-saving treatments.
That was the focus of the day two session at the Academy of Managed Care Pharmacy (AMCP)’s Annual Meeting, “Future of Cell and Gene Therapy Management: There is More Than Value Based Contracting!”
We caught up with one of the presenters, YuQian Liu, senior director of specialty clinical solutions at Prime Therapeutics/Magellan Rx, to talk about how managed care pharmacy professionals can rise to this challenge.
Stay tuned for additional coverage from AMCP Annual 2024 on our newsroom, and follow us on LinkedIn or X (formerly Twitter).
About Prime Therapeutics
Prime Therapeutics LLC (Prime) is a diversified pharmacy solutions organization. We offer innovative pharmacy benefit management, specialty and medical drug management, and state government solutions to millions of people across the country. At Prime, we’re reimagining pharmacy solutions to provide the care we’d want for our loved ones. We challenge the way it’s always been done to develop intelligently designed solutions that deliver savings, simplicity and support to help people achieve better health. For more information, visit us at PrimeTherapeutics.com or follow us on LinkedIn.